ReviewFrontiers in pediatrics2020
Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches.
Review in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04912726 (Efficacy and Safety of Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension: a Clinical Trial
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses.Paediatric drugs · 2023Pooled it
- Methods for establishing animal models of persistent pulmonary hypertension of the newborn: A systematic literature analysis.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesPooled it
- Nebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial.European journal of pediatrics · 2025Trial
- Optimized Contrast-Enhanced Micro-Computed Tomography for Simultaneous Imaging of the Ductus Arteriosus and Pulmonary Arteries During the Perinatal Transition.Pulmonary circulation · 2026Article
- Global Burden of Pediatric Pulmonary Arterial Hypertension, 1990-2021: A Systematic Analysis from the Global Burden of Disease Study 2021.Pediatric cardiology · 2026Article
- Clinical profile, survival outcomes, and predictors of mortality in neonates with persistent pulmonary hypertension: a follow-up study from Hawassa, Ethiopia.BMC pediatrics · 2026Article
- Maternal Analgesic Exposure and Fetal Ductal Constriction: A Prospective Cohort Study in Late Pregnancy.Birth defects research · 2026Article
- Mitochondrial quality control mechanisms as molecular targets for impaired lung development: from fetuses to neonates.Respiratory research · 2025Review
- Very rare combination of Pierre Robin sequence with patent ductus arteriosus, severe persistent pulmonary hypertension, and sepsis in an Afghan neonate: a case report and literature review.Oxford medical case reports · 2025Article
- Review of Precision Medicine and Diagnosis of Neonatal Illness.Diagnostics (Basel, Switzerland) · 2025Review
- Metagenomic Analysis of Gut Microbiome of Persistent Pulmonary Hypertension of the Newborn.Cardiovascular toxicology · 2025Article
- Central venous pressure dynamics in neonates with hypoxic-ischemic encephalopathy: insights into high mean airway pressure, PPHN, and ECMO management.Frontiers in pediatrics · 2025Article
- Global, regional and national trends in the burden of persistent pulmonary hypertension of the newborn and essentials of its management from 1993 to 2023: a scoping review.Frontiers in pediatrics · 2025Review
- Milrinone in persistent pulmonary hypertension of newborn: a scoping review.Pediatric research · 2024Article
- Review
- Caesarean section and respiratory system disorders in newborns.European journal of obstetrics & gynecology and reproductive biology: X · 2024Review
- Monitoring persistent pulmonary hypertension of the newborn using the arterial to end tidal carbon dioxide gradient.Journal of clinical monitoring and computing · 2024Observational
- Exploring the pathogenesis of pulmonary vascular disease.Frontiers in medicine · 2024Review
- Modelling and Simulation of the Combined Use of IABP and Impella as a Rescue Procedure in Cardiogenic Shock: An Alternative for Non-Transplant Centres?Bioengineering (Basel, Switzerland) · 2023Article
- Evidence-Based Guidelines for Acute Stabilization and Management of Neonates with Persistent Pulmonary Hypertension of the Newborn.American journal of perinatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent pulmonary hypertension of the newborn (PPHN) is one of the main causes of neonatal morbidity and mortality. It is characterized by sustained elevation of pulmonary vascular resistance (PVR), preventing an increase in pulmonary blood flow after birth. The affected neonates fail to establish blood oxygenation, precipitating severe respiratory distress, hypoxemia, and eventually death. Inhaled nitric oxide (iNO), the only approved pulmonary vasodilator for PPHN, constitutes, alongside supportive therapy, the basis of its treatment. However, nearly 40% of infants are iNO resistant. The cornerstones of increased PVR in PPHN are pulmonary vasoconstriction and vascular remodeling. A better understanding of PPHN pathophysiology may enlighten targeted and more effective therapies. Sildenafil, prostaglandins, milrinone, and bosentan, acting as vasodilators, besides glucocorticoids, playing a role on reducing inflammation, have all shown potential beneficial effects on newborns with PPHN. Furthermore, experimental evidence in PPHN animal models supports prospective use of emergent therapies, such as soluble guanylyl cyclase (sGC) activators/stimulators, l-citrulline, Rho-kinase inhibitors, peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists, recombinant superoxide dismutase (rhSOD), tetrahydrobiopterin (BH4) analogs, ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs), 5-HT2A receptor antagonists, and recombinant human vascular endothelial growth factor (rhVEGF). This review focuses on current knowledge on alternative and novel pathways involved in PPHN pathogenesis, as well as recent progress regarding experimental and clinical evidence on potential therapeutic approaches for PPHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.